Search DIAN Data Resource Requests

Title:Rates of longitudinal microstructural change in familial AD using diffusion weighted imaging

Date of Request:11/11/2013

Status:IP

ID:DIAN-D1315

Aim 1:Estimate rates of change in microstructure diffusion measurements (FA, MD, radial and axial diffusivity) in familial Alzheimer’s disease

Aim 2:Determine at what point in time do these changes diverge from non-carriers

Aim 3:Calculate sample sizes needed to detect a substantial treatment effect within a clinical trial similar to the population that will enter the DIAN clinical trials

Title:Imaging and biomarker correlates of spastic paraparesis associated with PSEN1 mutations

Date of Request:11/21/2013

Status:IP

ID:DIAN-D1316

Aim 1:To compare white matter, among persons with PSEN1 mutations, between those with and without spastic paraparesis using DTI

Aim 2:To compare cerebral amyloidosis, among persons with PSEN1 mutations, between those with and without spastic paraparesis using PIB images

Title:Plasma and cerebrospinal fluid phospholipid profiles in a DIAN cohort subset

Date of Request:11/22/2013

Status:A

ID:DIAN-D1317

Aim 1:To find phospholipid species which significantly differ in concentrations between mutation carriers and non carriers.

Aim 2:To correlate the phospholipid species obtained in aim 1, with the established gold standard biomarkers such as PiB-PET SUVR, cerebrospinal fluid concentrations of total-tau, phosphorylated-tau and Aβ42.

Aim 3:correlate the plasma phospholipid species obtained in aim 1, with FDG-PET SUVR, MRI data and plasma Abeta levels.

Title:Alzheimer's Disease Biomarkers via a Multimodal statistical approach

Date of Request:12/11/2013

Status:IP

ID:DIAN-D1318

Aim 1:Determine imaging and clinical biomarkers for the risk of Alzheimer's Diease

Aim 2:Conceputalize a target sample size that could be used for clinical trials based on the power of targeted biomarkers

Title:Patch-Based Analysis of Anatomical Brain Asymmetry

Date of Request:12/19/2013

Status:IA

ID:DIAN-D1319

Aim 1:Identify characteristic structural asymmetry patterns in diseased individuals versus healthy controls

Title:Cerebral Amyloid Angiopathy due to APP mutation: Clinicopathological manifestations and brain imaging findings

Date of Request:1/7/2014

Status:IP

ID:DIAN-D1401

Aim 1:1. To investigate the clinicopathological features of cerebral amyloid angiopathy in an HCHWA-Dutch Type kindred

Aim 2:2. To investigate the CSF and Blood biomarkers related to Alzheimer’s disease in the APP Dutch Type mutation carriers and non-carriers

Aim 3:3. To compare the mutation carriers and non-carriers' on MRI, FDG and PiB PET imaging results

Aim 44. To compare the mutation carriers and non-carriers on clinical, cognitive and personality measures

Title:Brain and cognitive reserve capacities in DIAN participants

Date of Request:1/8/2014

Status:IP

ID:DIAN-D1402

Aim 1:1. To examine whether DIAN participants differ in terms of their brain reserve (as indicated by brain volume, cortical thickness, white matter hyper intensities etc.) and cognitive reserve (as indicated by education years and Hollingshead Index of Social Position).

Aim 2:2. 2. To examine if cognitive and brain reserves indices are associated with delay in clinical manifestation of the AD.

Aim 3:3. 3. To Compare these groups on blood and CSF biomarkers and imaging results at baseline and follow ups

Aim 44. 4. To investigate whether higher baseline cognitive function delays the age at onset?

Title:Vital signs in the different stages of dominantly inherited Alzheimer`s disease

Date of Request:2/17/2014

Status:A

ID:DIAN-D1403

Aim 1:To compare vital signs between mutation carriers (MC) and non-mutation carriers (NMC) at different clinical stages as assessed with Clinical Dementia Rating (CDR) scale.

Aim 2:To compare vital signs between MC and NMC as a function of estimated years to onset (EYO).

Aim 3:To determine the association between vital signs and clinical parameters (age, gender, EYO, GDS), psychometric parameters (MMSE, CDR global, CDR sum of boxes, Logical Memory, delayed recall), biochemical biomarkers (CSF levels of Abeta 1-42 and tau) and neuro-imaging biomarkers (PiB-PET SUVR).

Title:QSM analysis of susceptibility weighted imaging data

Date of Request:3/26/2014

Status:A

ID:DIAN-D1404

Aim 1:development of quantitative susceptibility mapping as a novel biomarker in preclinical AD

Aim 2:To examine whether early basal ganglia PIB ligand uptake is associated with altered iron levels

Title:Understanding attitudes toward clinical trials among persons at risk for autosomal dominant Alzheimer's disease

Date of Request:6/3/2014

Status:IP

ID:DIAN-D1405

Aim 1:To characterize the differences in DIAN participants who do and do not want to know their genetic status

Aim 2:To examine the proportion of at-risk individuals who would change their mind whether to undergo genetic testing in the setting of a clinical trial and to characterize differences in these participants, compared to those continue to refuse genetic testing

Aim 3:To assess the effects of the possibility of receiving placebo and varying drug/placebo ratios on persons’ desire to undergo genetic testing and participate in a clinical trial

Aim 4To assess the effects of the possibility of an open-label extension on persons’ desire to undergo genetic testing and participate in a clinical trial